A Double-Blind Clinical Trial of Hydroxyethylrutosides in the Treatment of the Symptoms and Signs of Chronic Venous Insufficiency

Abstract

Objective:

To study the safety and efficacy of hydroxyethylrutosides (HR) in patients with chronic venous insufficiency (CVI) (Widmer grade II) and examine any correlation with objective measurements (plethysmography and TcPo₂).

Design:

Double-blind, randomized, placebo-controlled, multicentre trial.

Setting:

One outpatient university angiology clinic, one outpatient angiology clinic in a military hospital and one private angiological consultation, all in the Paris area.

Patients:

One hundred and nine patients with grade II Widmer CVI, confirmed by echo-Doppler and plethysmography. Elastic stockings were excluded. After five exclusions, 53 received HR and 51 placebo.

Interventions:

Patients randomized to one sachet of 1 g HR twice daily (or placebo) for 2 months, after a 1 month placebo run-in period. Examinations on entry to the trial (T_–1), after 1 month run-in (T_–0) and after 1 (T₊₁) and 2 months (T₊₂) treatment.

Main outcome measures:

These were measured at each of the four visits. Primary outcome: minimal ankle and maximal calf circumferences. Secondary outcomes: five individual leg symptoms and total symptom score, pitting oedema. Plethysmography (six calculated variables) and TcPo₂.

Results:

The reduction of both ankle and calf circumferences was significantly greater in the HR group (p<0.0001), as was pitting oedema (p<0.001), the five individual symptoms and the total symptom score (p<0.001). Of the plethysmographic findings, there was a significant reduction in maximum venous outflow (p<0.001 at T₊₁ and p<0.05 at T₊₂). Overall there was no significant change in TcPo₂.

Conclusions:

HR is an effective and well-tolerated treatment for leg oedema and symptoms of patients with CVI.